The Laforin-Malin Complex Negatively Regulates Glycogen Synthesis by Modulating Cellular Glucose Uptake via Glucose Transporters

REFERENCES

• Becker M, Newman S, Ismail-Beigi F. 1996. Stimulation of GLUT1 glucose transporter expression in response to inhibition of oxidative phosphorylation: role of reduced sulfhydryl groups. Mol. Cell. Endocrinol. 121:165–170.
   PubMedGoogle Scholar
• Bell B, Xing H, Yan K, Gautam N, Muslin AJ. 1999. KSR-1 binds to G-protein βγ subunits and inhibits βγ-induced mitogen-activated protein kinase activation. J. Biol. Chem. 274:7982–7986.
   PubMedGoogle Scholar
• Boer P, Sperling O. 2004. Modulation of glycogen phosphorylase activity affects 5-phosphoribosyl-1-pyrophosphate availability in rat hepatocyte cultures. Nucleosides Nucleotides Nucleic Acids 23:1235–1239.
   PubMed Web of Science ®Google Scholar
• Carruthers A, DeZutter J, Ganguly A, Devaskar SU. 2009. Will the original glucose transporter isoform please stand up! Am. J. Physiol. 297:E836–E848.
   Web of Science ®Google Scholar
• Chan EM, et al. 2004. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Hum. Mol. Genet. 13:1117–1129.
   PubMedGoogle Scholar
• Chan EM, et al. 2003. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat. Genet. 35:125–127.
   PubMed Web of Science ®Google Scholar
• Cheng A, et al. 2007. A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease. Genes Dev. 21:2399–2409.
   PubMedGoogle Scholar
• Cid E, Cifuentes D, BaquÉ S, Ferrer JC, Guinovart JJ. 2005. Determinants of the nucleocytoplasmic shuttling of muscle glycogen synthase. FEBS J. 272:3197–3213.
   PubMedGoogle Scholar
• Coore HG, Randle PJ. 1964. Inhibition of glucose phosphorylation by mannoheptulose. Biochem. J. 91:56–59.
   PubMedGoogle Scholar
• Davies SP, Carling D, Hardie DG. 1989. Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. Eur. J. Biochem. 186:123–128.
   PubMedGoogle Scholar
• DePaoli-Roach AA, et al. 2010. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to Lafora bodies and the accumulation of insoluble laforin. J. Biol. Chem. 285:25372–25381.
   PubMedGoogle Scholar
• Dombrowski L, Roy D, Marcotte B, Marette A. 1996. A new procedure for the isolation of plasma membranes, T tubules, and internal membranes from skeletal muscle. Am. J. Physiol. 270:E667–E676.
   PubMedGoogle Scholar
• Dubey D, Ganesh S. 2008. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Hum. Mol. Genet. 17:3010–3020.
   PubMedGoogle Scholar
• Fernández-Sánchez ME, et al. 2003. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum. Mol. Genet. 12:3161–3171.
   PubMedGoogle Scholar
• Ganesh S, et al. 2000. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum. Mol. Genet. 9:2251–2261.
   PubMed Web of Science ®Google Scholar
• Ganesh S, et al. 2002. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum. Mol. Genet. 11:1251–1262.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Puri R, Singh S, Mittal S, Dubey D. 2006. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J. Hum. Genet. 51:1–8.
   PubMed Web of Science ®Google Scholar
• Ganesh S, et al. 2004. The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies. Biochem. Biophys. Res. Commun. 313:1101–1109.
   PubMedGoogle Scholar
• Garyali P, et al. 2009. The laforin-malin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system. Hum. Mol. Genet. 18:688–700.
   PubMedGoogle Scholar
• Gentry MS, Worby CA, Dixon JE. 2005. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc. Natl. Acad. Sci. U. S. A. 102:8501–8506.
   PubMed Web of Science ®Google Scholar
• Guinez C, et al. 2008. Protein ubiquitination is modulated by O-GlcNAc glycosylation. FASEB J. 22:2901–2911.
   PubMedGoogle Scholar
• Hardie DG. 2007. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8:774–785.
   PubMed Web of Science ®Google Scholar
• Hawley SA, Gadalla AE, Olsen GS, Hardie DG. 2002. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51:2420–2425.
   PubMed Web of Science ®Google Scholar
• Hresko RC, Heimberg H, Chi MM, Mueckler M. 1998. Glucosamine-induced insulin resistance in 3T3-L1 adipocytes is caused by depletion of intracellular ATP. J. Biol. Chem. 273:20658–20668.
   PubMed Web of Science ®Google Scholar
• James LR, et al. 2002. Flux through the hexosamine pathway is a determinant of nuclear factor κB-dependent promoter activation. Diabetes 51:1146–1156.
   PubMedGoogle Scholar
• Johnston M. 1999. Feasting, fasting and fermenting. Glucose sensing in yeast and other cells. Trends Genet. 15:29–33.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Y, Wu C, Liu Y, Zheng P. 2006. Dimerization of laforin is required for its optimal phosphatase activity, regulation of GSK3β phosphorylation, and Wnt signaling. J. Biol. Chem. 28:34768–34774.
   Google Scholar
• Luiken JJ, et al. 2004. Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch. 448:1–15.
   PubMed Web of Science ®Google Scholar
• Luo B, et al. 2007. Chronic hexosamine flux stimulates fatty acid oxidation by activating AMP-activated protein kinase in adipocytes. J. Biol. Chem. 282:7172–7180.
   PubMedGoogle Scholar
• Marshall S, Nadeau O, Yamasaki K. 2005. Glucosamine-induced activation of glycogen biosynthesis in isolated adipocytes. Evidence for a rapid allosteric control mechanism within the hexosamine biosynthesis pathway. J. Biol. Chem. 280:11018–11024.
   PubMedGoogle Scholar
• Medina RA, Owen GI. 2002. Glucose transporters: expression, regulation and cancer. Biol. Res. 35:9–26.
   PubMed Web of Science ®Google Scholar
• Minassian BA, et al. 1998. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. 20:171–174.
   PubMed Web of Science ®Google Scholar
• Mittal S, Dubey D, Yamakawa K, Ganesh S. 2007. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum. Mol. Genet. 16:753–762.
   PubMed Web of Science ®Google Scholar
• Munekata K, Sakamoto K. 2009. Forkhead transcription factor Foxo1 is essential for adipocyte differentiation. In Vitro Cell. Dev. Biol. Anim. 45:642–651.
   PubMed Web of Science ®Google Scholar
• Polekhina G, et al. 2003. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr. Biol. 13:867–871.
   PubMed Web of Science ®Google Scholar
• Puri R, Suzuki T, Yamakawa K, Ganesh S. 2009. Hyperphosphorylation and aggregation of tau in laforin-deficient mice, an animal model for Lafora disease. J. Biol. Chem. 284:22657–22663.
   PubMed Web of Science ®Google Scholar
• Romá-Mateo C, et al. 2011. Laforin, a dual-specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase. Biochem. J. 439:265–275.
   PubMedGoogle Scholar
• Salt IP, Johnson G, Ashcroft SJ, Hardie DG. 1998. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem. J. 335:533–539.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Badwar I, Upadhyay M, Singh S, Ganesh S. 2011. Malin and laforin are essential components of a protein complex that protects cells from the thermal stress. J. Cell Sci. 124:2277–2286.
   PubMed Web of Science ®Google Scholar
• Shin BC, McKnight RA, Devaskar SU. 2004. Glucose transporter GLUT8 translocation in neurons is not insulin responsive. J. Neurosci. Res. 75:835–844.
   PubMed Web of Science ®Google Scholar
• Singh S, Ganesh S. 2009. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum. Mutat. 30:715–723.
   PubMed Web of Science ®Google Scholar
• Solaz-Fuster MC, et al. 2008. Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway. Hum. Mol. Genet. 17:667–678.
   PubMedGoogle Scholar
• Tagliabracci VS, et al. 2007. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc. Natl. Acad. Sci. U. S. A. 104:19262–19266.
   PubMedGoogle Scholar
• Tagliabracci VS, et al. 2008. Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J. Biol. Chem. 283:33816–33825.
   PubMedGoogle Scholar
• Tagliabracci VS, et al. 2011. Phosphate incorporation during glycogen synthesis and Lafora disease. Cell. Metab. 13:274–282.
   PubMedGoogle Scholar
• Vernia S, et al. 2009. AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and accelerates its down-regulation by the laforin-malin complex. J. Biol. Chem. 284:8247–8255.
   PubMedGoogle Scholar
• Vernia S, et al. 2011. Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice. Hum. Mol. Genet. 20:2571–2584.
   PubMedGoogle Scholar
• Vilchez D, et al. 2007. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat. Neurosci. 10:1407–1413.
   PubMed Web of Science ®Google Scholar
• Wang J, Stuckey JA, Wishart M, Dixon JE. 2002. A unique carbohydrate binding domain targets the Lafora disease phosphatase to glycogen. J. Biol. Chem. 277:2377–2380.
   PubMed Web of Science ®Google Scholar
• Wolfsdorf JI, Holm IA, Weinstein DA. 1999. Glycogen storage diseases: phenotypic, genetic, and biochemical characteristics, and therapy. Endocrinol. Metab. Clin. North. Am. 4:801–823.
   Google Scholar
• Yokoi S, Austin J, Witmer F, Sakai M. 1968. Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases. Arch. Neurol. 19:15–33.
   PubMedGoogle Scholar
• Yokoi S, Nakayama H, Negishi T. 1975. Biochemical studies on tissues from a patient with Lafora disease. Clin. Chim Acta 62:415–423.
   PubMedGoogle Scholar
• Zhong D, et al. 2008. 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol. Cancer Ther. 4:809–817.
   Google Scholar